Armonk, NY, United States of America

Song Nie

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Song Nie

Introduction

Song Nie is an accomplished inventor based in Armonk, NY (US). He has made significant contributions to the field of biotherapeutics through his innovative research and development efforts. His work primarily focuses on improving the recovery of hydrophobic peptides, which are crucial in various pharmacokinetic analyses.

Latest Patents

Song Nie holds a patent titled "Maximizing hydrophobic peptide recovery using a mass spectrometry compatible surfactant." This invention pertains to methods of characterizing peptides or proteins of interest. Specifically, it involves the use of the nonionic surfactant DDM to enhance the recovery of hydrophobic peptides in pharmacokinetic studies, reduced peptide mapping, and other biotherapeutic protein analyses. He has 1 patent to his name.

Career Highlights

Song Nie is currently employed at Regeneron Pharmaceuticals, Inc., a leading biotechnology company known for its innovative approaches to drug development. His role at Regeneron allows him to apply his expertise in peptide recovery and mass spectrometry to advance biotherapeutic research.

Collaborations

Throughout his career, Song has collaborated with notable colleagues, including Reid O'Brien Johnson and Tyler Greer. These collaborations have further enriched his research and contributed to the success of various projects within the company.

Conclusion

In summary, Song Nie is a prominent inventor whose work in maximizing hydrophobic peptide recovery has significant implications for biotherapeutic protein analyses. His contributions continue to shape the landscape of pharmaceutical research and development.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…